MCID: SMT006
MIFTS: 51

Somatoform Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Somatoform Disorder

MalaCards integrated aliases for Somatoform Disorder:

Name: Somatoform Disorder 12 14 69
Physiological Malfunction Arising from Mental Factor 12
Psychophysiologic Disorders 69
Psychosomatic Disorder 12

Classifications:



Summaries for Somatoform Disorder

Disease Ontology : 12 A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate.

MalaCards based summary : Somatoform Disorder, also known as physiological malfunction arising from mental factor, is related to personality disorder and somatization disorder, and has symptoms including dyspnea, headache and meningism. An important gene associated with Somatoform Disorder is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Th17 cell differentiation and Neuroscience. The drugs Pregabalin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and cortex, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Somatoform Disorder

Diseases related to Somatoform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
id Related Disease Score Top Affiliating Genes
1 personality disorder 30.8 COMT OPRM1 TRPV1
2 somatization disorder 11.7
3 hypochondriasis 11.3
4 conversion disorder 11.1
5 psychogenic movement 11.1
6 body dysmorphic disorder 11.1
7 pain disorder 11.1
8 dissociative seizures 10.7
9 toxic optic neuropathy 10.7 IL1A IL1B
10 ileitis 10.7 IL1B IL4
11 eye accommodation disease 10.7 IL2RA IL4
12 autoimmune inner ear disease 10.7 FAAH TRPV1
13 cyclotropia 10.6 COMT OPRM1
14 gastric cancer risk after h. pylori infection 10.6 IL1B IL1RN
15 lymphoma 10.6 IL1B IL4 TRPV1
16 dementia - subcortical 10.6 COMT OPRM1
17 lacrimal system cancer 10.5 IL1B IL4 TRPV1
18 scrotal carcinoma 10.5 IL1A IL1B
19 walker dyson syndrome 10.5 IL1B IL1RN
20 anxiety disorder 10.5
21 legionellosis 10.5 IL1A IL1B IL4
22 polyneuropathy due to drug 10.5 IL1A IL4
23 chitty hall webb syndrome 10.5 COMT TPH1
24 germ cell and embryonal cancer 10.5 IL1A IL1B IL4
25 cerebellar disease 10.5 IL1A IL1B IL4
26 parkinsonism-dystonia, infantile 10.5 COMT OPRM1 TPH1
27 noma 10.5 IL1B IL1RN IL4
28 hereditary multiple exostoses 10.5 COMT FAAH IL1B
29 panic disorder 10.5
30 vulva fibroepithelial polyp 10.5 IL1A IL1B IL4
31 gliosarcoma 10.4 IL1A IL1B
32 mental retardation dysmorphism hypogonadism diabetes 10.4 IL1A IL1B IL1RN
33 discoid lupus erythematosus of eyelid 10.4 IL1A IL1B IL4
34 glossitis 10.4 IL1A IL1B IL1RN
35 milk allergy 10.4 IL1B IL1RN
36 askin's tumor 10.4 IL1A IL1B IL1RN
37 sinusitis 10.4 IL1A IL1B IL1RN
38 insensitivity to pain, congenital 10.4 SCN9A TRPV1
39 pleomorphic lipoma 10.4 IL1A IL1B IL1RN
40 granulomatous orchitis 10.4 IL1A IL1B IL4
41 hypermobility of coccyx 10.4 NGF TRPV1
42 band keratopathy 10.4 IL1A IL1B OPRM1
43 epulis 10.4 IL1B TAC1 TRPV1
44 obsessive-compulsive disorder 10.4
45 esophagus melanoma 10.4 IL1RN IL2RA IL4
46 chancroid 10.4 IL1B IL4
47 esophageal candidiasis 10.4 IL1A IL2RA IL4
48 myositis fibrosa 10.3 TAC1 TPH1 TRPV1
49 eyelid neoplasm 10.3 IL4 TAC1 TRPV1
50 dehydration polycythemia 10.3 IL4 TAC1 TRPV1

Graphical network of the top 20 diseases related to Somatoform Disorder:



Diseases related to Somatoform Disorder

Symptoms & Phenotypes for Somatoform Disorder

UMLS symptoms related to Somatoform Disorder:


dyspnea, headache, meningism, pain, paresis, reflex, abnormal, seizures, vertigo, multiple somatic complaints, neurobehavioral manifestations, labored breathing, neuromuscular manifestations, symptoms

MGI Mouse Phenotypes related to Somatoform Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 COMT FAAH IL1A IL1B IL1RN IL2RA
2 cardiovascular system MP:0005385 9.92 COMT IL1A IL1B IL1RN NGF TAC1
3 immune system MP:0005387 9.9 TRPV1 CABIN1 COMT IL1A IL1B IL1RN
4 integument MP:0010771 9.73 OPRM1 SCN9A TAC1 TPH1 TRPA1 TRPV1
5 nervous system MP:0003631 9.28 COMT FAAH IL1B IL4 NGF OPRM1

Drugs & Therapeutics for Somatoform Disorder

Drugs for Somatoform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
3
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
4 Piracetam Approved Phase 4 7491-74-9
5
Fluoxetine Approved, Vet_approved Phase 4,Phase 1,Phase 2 54910-89-3 3386
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 401 6234
8
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-84-3 187
14
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
15
Flunarizine Approved Phase 4 52468-60-7 941361
16
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
17
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
20
Norepinephrine Approved Phase 4 51-41-2 439260
21
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
22 Etiracetam Investigational Phase 4 33996-58-6
23 Mosapride Investigational Phase 4 112885-41-3
24
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
25 Anticoagulants Phase 4,Phase 2
26 Pentosan Sulfuric Polyester Phase 4
27 Anticonvulsants Phase 4,Phase 3,Phase 2
28 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 1,Phase 2
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
33
Serotonin Phase 4,Phase 3,Phase 1,Phase 2 50-67-9 5202
34 Serotonin Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
36 Anesthetics Phase 4,Phase 3,Phase 2
37 Anesthetics, Local Phase 4,Phase 3,Phase 2
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Anxiety Agents Phase 4,Phase 3
42 Antiparkinson Agents Phase 4,Phase 3
43 calcium channel blockers Phase 4,Phase 3
44 Calcium, Dietary Phase 4,Phase 3,Phase 2
45 Tranquilizing Agents Phase 4,Phase 3
46 Antipsychotic Agents Phase 4
47 Autonomic Agents Phase 4,Phase 3
48 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
49 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
50 triamcinolone acetonide Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 226)

id Name Status NCT ID Phase Drugs
1 Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome Unknown status NCT01895153 Phase 4
2 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
3 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4 Fluoxetine;Placebo
4 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
5 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
6 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4 Lidocaine injection
7 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
8 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
9 GRASSP: Gralise® for Spine Surgery Pain Recruiting NCT01764464 Phase 4 Gralise®;Placebo
10 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4 flunarizine and/or pregabalin
11 Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders Recruiting NCT03036293 Phase 4 Tenoten;Placebo
12 Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic Active, not recruiting NCT02007928 Phase 4
13 CBT as an Adjunct to SRIs in the Treatment of BDD Terminated NCT00211809 Phase 4 Venlafaxine
14 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
15 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Terminated NCT01879930 Phase 4 doxycycline;placebo
16 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4
17 Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study Terminated NCT01280747 Phase 4
18 Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome Terminated NCT00780390 Phase 4
19 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
20 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
21 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
22 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
23 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
24 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
25 Psychological Prevention of Internalizing Disorders Unknown status NCT00564239 Phase 3
26 DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Completed NCT00130988 Phase 3
27 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
28 Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Completed NCT01119469 Phase 3
29 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
30 Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
31 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
32 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
33 Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus Completed NCT00381771 Phase 2, Phase 3
34 Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
35 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders Completed NCT00769561 Phase 2, Phase 3
36 A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. Completed NCT00246142 Phase 3 Botulinum type A toxin (Dysport)
37 Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) Completed NCT00817128 Phase 2, Phase 3
38 A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1 Completed NCT00166452 Phase 3 Lenalidamide
39 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
40 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
41 Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
42 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
43 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Recruiting NCT02390505 Phase 3 Vitamin C;Placebo
44 Treatment of Globus Sensations With Psychotherapy Active, not recruiting NCT01590992 Phase 2, Phase 3
45 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles Not yet recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
46 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
47 Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions Unknown status NCT01316627 Phase 2
48 The Use of Zoledronic Acid to Complex Regional Pain Syndrome Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
49 Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Unknown status NCT00377468 Phase 2 Delta9-Tetrahydrocannabinol
50 Rehabilitation of Conversion Gait Disorder Unknown status NCT01422278 Phase 1, Phase 2

Search NIH Clinical Center for Somatoform Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Somatoform Disorder

Anatomical Context for Somatoform Disorder

MalaCards organs/tissues related to Somatoform Disorder:

39
Prostate, Brain, Cortex, Testes, Prefrontal Cortex, Spinal Cord, Bone

Publications for Somatoform Disorder

Articles related to Somatoform Disorder:

(show top 50) (show all 103)
id Title Authors Year
1
Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study. ( 28471951 )
2017
2
The CIPRUS study, a nurse-led psychological treatment for patients with undifferentiated somatoform disorder in primary care: study protocol for a randomised controlled trial. ( 28468642 )
2017
3
Somatic symptom disorder and undifferentiated somatoform disorder, which is broader? Response to "Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS)". ( 27542553 )
2016
4
Harm avoidance and persistence are associated with somatoform disorder psychopathology: A study in Taiwan. ( 26919056 )
2016
5
Cognitive Alexithymia Mediates the Association Between Avoidant Attachment and Interpersonal Problems in Patients With Somatoform Disorder. ( 27185015 )
2016
6
Suicidality in patients with somatoform disorder - the speechless expression of anger? ( 27821358 )
2016
7
Depression and anxiety among patients with somatoform disorders, panic disorder, and other depressive/anxiety disorders in Taiwan. ( 27179181 )
2016
8
Dysaesthetic penoscrotodynia may be a somatoform disorder: results from a two-centre retrospective case series. ( 26932754 )
2016
9
The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders. ( 26785798 )
2016
10
Intensive multidisciplinary treatment of severe somatoform disorder: a prospective evaluation. ( 25594786 )
2015
11
Insecure attachment strategies are associated with cognitive alexithymia in patients with severe somatoform disorder. ( 26060261 )
2015
12
The day-to-day concurrence of bodily complaints and affect in patients with severe somatoform disorder. ( 26032264 )
2015
13
Fibromyalgia syndrome: a somatoform disorder? ( 24453056 )
2014
14
Relationship between alexithymia and coping strategies in patients with somatoform disorder. ( 24403835 )
2014
15
Psychotherapy for severe somatoform disorder: problems with missing studies. ( 24590981 )
2014
16
Effectiveness of psychotherapy for severe somatoform disorder: meta-analysis. ( 24385460 )
2014
17
A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? ( 25388965 )
2014
18
Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. ( 24525655 )
2014
19
The spiral aftereffect technique (SAT) can differentiate between depressive and somatoform disorder patients. ( 24897884 )
2014
20
Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder? ( 25029686 )
2014
21
Somatoform disorders in patients with chronic pain. ( 24288382 )
2013
22
Cognitive and affective dimensions of difficulties in emotional functioning in somatoform disorders and borderline personality disorder. ( 23006331 )
2013
23
Changes in brain activity of somatoform disorder patients during emotional empathy after multimodal psychodynamic psychotherapy. ( 23966922 )
2013
24
Explanatory models of somatoform disorder patients attending a psychiatry outpatient clinic: A study from North India. ( 24029246 )
2013
25
Altered brain activity during emotional empathy in somatoform disorder. ( 21998038 )
2012
26
Gabapentin as add-on treatment for somatoform disorder: a case report. ( 22240859 )
2012
27
Definition and structure of body-relatedness from the perspective of patients with severe somatoform disorder and their therapists. ( 22905144 )
2012
28
Public familiarity with the terms somatoform disorder and functional disorder in Germany: results from a representative population survey. ( 22690365 )
2012
29
Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders. ( 22029732 )
2012
30
Rethinking the Psychogenic Model of Complex Regional Pain Syndrome: Somatoform Disorders and Complex Regional Pain Syndrome. ( 24223338 )
2012
31
Somatoform disorder and the DSM-V Workgroup's interim proposals: two central issues. ( 22664310 )
2012
32
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. ( 22367417 )
2012
33
Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. ( 22281461 )
2012
34
Relationship between neural activity and immunity in patients with undifferentiated somatoform disorder. ( 22801462 )
2012
35
Dysfunctional affect regulation in borderline personality disorder and in somatoform disorder. ( 22984638 )
2012
36
Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. ( 21785907 )
2012
37
Hypochondriasis, somatoform disorders, and anxiety disorders: sociodemographic variables, general psychopathology, and naturalistic treatment effects. ( 22551794 )
2012
38
Effect of tryptophan hydroxylase gene polymorphism on aggression in major depressive disorder and undifferentiated somatoform disorder. ( 22697203 )
2012
39
Childhood traumatization by primary caretaker and affect dysregulation in patients with borderline personality disorder and somatoform disorder. ( 22893813 )
2011
40
Serotonin-related gene pathways associated with undifferentiated somatoform disorder. ( 21531467 )
2011
41
Multimodal psychodynamic psychotherapy induces normalization of reward related activity in somatoform disorder. ( 21198419 )
2011
42
Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. ( 21762827 )
2011
43
A suspected case of somatoform disorder successfully treated with an herbal medicine. ( 21299430 )
2011
44
Somatoform disorder after conscious sedation. ( 22136794 )
2011
45
Association of somatoform disorder symptoms with genetic variants potentially involved in the modulation of nociception. ( 21037510 )
2011
46
Acoustic neuroma identified after electroconvulsive therapy in a patient with recurrent major depression and undifferentiated somatoform disorder. ( 20357670 )
2010
47
Towards positive diagnostic criteria: a systematic review of somatoform disorder diagnoses and suggestions for future classification. ( 20403499 )
2010
48
Causal symptom attributions in somatoform disorder and chronic pain. ( 20004296 )
2010
49
Affect dysregulation and dissociation in borderline personality disorder and somatoform disorder: differentiating inhibitory and excitatory experiencing states. ( 20938867 )
2010
50
The concept of comorbidity in somatoform disorder--a DSM-V alternative for the DSM-IV classification of somatoform disorder. ( 20004307 )
2010

Variations for Somatoform Disorder

Expression for Somatoform Disorder

Search GEO for disease gene expression data for Somatoform Disorder.

Pathways for Somatoform Disorder

Pathways related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.4 IL1A IL1B IL2RA IL4
2 12.31 COMT NGF OPRM1 SCN9A TPH1
3 12.26 CABIN1 IL1B IL1RN IL2RA IL4
4
Show member pathways
12.21 IL1A IL1B IL4 OPRM1
5
Show member pathways
11.95 IL1A IL1B IL4
6
Show member pathways
11.82 IL1A IL1B IL2RA
7 11.79 IL1A IL1B IL4
8
Show member pathways
11.75 IL1B IL2RA IL4
9 11.61 IL1A IL1B IL4 OPRM1
10 11.56 IL1B IL2RA IL4
11
Show member pathways
11.51 CABIN1 IL2RA IL4
12 11.44 IL1A IL1B IL2RA IL4
13 11.31 IL1A IL1B IL1RN NGF TAC1 TPH1
14 10.97 IL1A IL1B IL4
15 10.95 IL1A IL1B IL1RN IL4
16 10.69 IL1B IL4
17 10.28 IL1A IL1B

GO Terms for Somatoform Disorder

Biological processes related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 IL1A IL1B IL1RN IL2RA IL4
2 cell surface receptor signaling pathway GO:0007166 9.86 CABIN1 IL2RA TRPA1 TRPV1
3 inflammatory response GO:0006954 9.8 IL1A IL1B IL1RN IL2RA SCN9A TAC1
4 response to lipopolysaccharide GO:0032496 9.72 COMT GCH1 IL1B OPRM1 TAC1
5 positive regulation of T cell proliferation GO:0042102 9.63 IL1B IL2RA IL4
6 positive regulation of T cell differentiation GO:0045582 9.58 IL2RA IL4
7 microglial cell activation GO:0001774 9.57 IL4 TRPV1
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 IL1A IL1B
9 sensory perception of pain GO:0019233 9.55 OPRM1 SCN9A TAC1 TRPA1 TRPV1
10 behavioral response to pain GO:0048266 9.54 SCN9A TRPV1
11 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.54 IL1A IL1B IL4
12 positive regulation of chemokine biosynthetic process GO:0045080 9.52 IL1B IL4
13 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.51 IL1A IL1B
14 ectopic germ cell programmed cell death GO:0035234 9.48 IL1A IL1B
15 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.43 TRPA1 TRPV1
16 thermoception GO:0050955 9.4 TRPA1 TRPV1
17 fever generation GO:0001660 9.13 IL1A IL1B TRPV1
18 response to pain GO:0048265 9.02 COMT GCH1 TAC1 TRPA1 TRPV1

Molecular functions related to Somatoform Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL1A IL1B IL1RN IL4
2 calcium-release channel activity GO:0015278 9.16 TRPA1 TRPV1
3 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B IL1RN

Sources for Somatoform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....